The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA

Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA

August 1, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report.

You Might Also Like
  • Higher Tocilizumab Dose Plus Methotrexate Best for Early RA
  • Effects of Obesity on Sustained Remission in Early RA
  • Adding Prednisone to Methotrexate May Be Helpful in Early RA

Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18 in Annals of the Rheumatic Diseases. But questions regarding the optimal dosage and combination of drugs remain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Diederik De Cock from KU Leuven and colleagues in the CareRA trial compared the effectiveness of different initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) combinations, with or without glucocorticoid remission induction, in 289 high-risk and 90 low-risk patients with early RA.

High-risk patients were randomized to COBRA Classic (weekly methotrexate, daily sulfasalazine and a weekly step-down scheme of oral prednisone); COBRA Slim (weekly methotrexate with a weekly step-down scheme of oral prednisone); or COBRA Avant Garde (weekly methotrexate, daily leflunomide and a weekly step-down scheme of oral prednisone). Low-risk patients were randomized to COBRA Slim or methotrexate tight step-up (with no oral steroids allowed).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the high-risk group, there were no differences in the primary outcome—remission at Week 52 as defined by DAS28(CRP) below 2.6—between the treatments.

Similarly, the low-risk group had remission rates of 67.4% with COBRA Slim and 57.4% with methotrexate tight step-up (p=0.329).

There were more treatment adaptations and glucocorticoid injections in COBRA Slim patients, and there were numerically fewer therapy-related adverse events with COBRA Slim than with the other regimens, although these differences were small and did not achieve statistical significance.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We propose an effective, safe, feasible and standardized initial treat-to-target strategy, COBRA Slim, yielding excellent results in all patients with early RA regardless of classical prognostic markers, with high remission rates and low numbers of patients remaining on chronic glucocorticoids or biological therapy,” the researchers conclude.

The study had no commercial funding, and the researchers reported no conflicting interests.

Dr. De Cock did not respond to a request for comments.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: glucocorticoid, Methotrexate, Remission, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Higher Tocilizumab Dose Plus Methotrexate Best for Early RA
  • Effects of Obesity on Sustained Remission in Early RA
  • Adding Prednisone to Methotrexate May Be Helpful in Early RA
  • Triple Therapy with Methotrexate Effective, Cheaper in RA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)